On March 3, 2026, Arbutus Biopharma Corp announced a settlement with Moderna regarding patent infringement, requiring Moderna to pay $950 million upfront and potentially an additional $1.3 billion contingent on future court outcomes. This settlement resolves litigation on Moderna’s use of Arbutus's lipid nanoparticle technology in its vaccines.